In short
Clinical trials are investigating Losartan in patients with kidney disease and heart failure. These studies look at safety, benefit, and treatment results in different groups, including adults with IgA nephropathy, focal segmental glomerulosclerosis, and heart failure. Some trials also compare Losartan with other treatments or use it as part of standard care.
Key points
- Clinical trials investigating Losartan are focused on kidney disease and heart failure. The trial data include adults with focal segmental glomerulosclerosis, IgA nephropathy, and heart failure. The studies are in Phase 3 and Phase 4, which means they are later-stage trials with larger patient groups. Main outcomes include urine protein measures, kidney function, death, heart failure readmission, worsening heart failure, quality of life, and treatment adherence. Some trials compare Losartan-related care with other treatments or use it as part of broader standard treatment.
Clinical trial overview
The trial data show three interventional studies that include Losartan in the treatment plan or as a study treatment option. These studies focus on kidney disease and heart failure, which are serious long-term conditions.
All three studies are marked Authorised, and they are in later trial stages, with Phase 3 and Phase 4 designs. This means the research is aimed at understanding how well the studied treatments work in larger patient groups and how they perform over time.
Kidney disease studies
One study is titled Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis and includes adults with focal segmental glomerulosclerosis (FSGS). FSGS is a kidney disease that can cause protein loss in the urine and declining kidney function.
This Phase 3 study has an enrollment of 308 people and is designed to evaluate the effect of DMX-200 on urine protein and kidney function in adults with FSGS who are receiving an ARB. An ARB is a type of treatment used in the study population, and Losartan is listed in the trial data as one of the drugs in this research context.
The other kidney study is Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3). It includes adults with IgA Nephropathy, another kidney disease that can lead to protein in the urine.
This Phase 4 study has an enrollment of 481 people and compares atacicept with placebo while also listing Losartan and enalapril in the intervention data. The main kidney outcome is the urine protein to creatinine ratio (UPCR), measured at week 24 in Phase 2b and week 36 in Phase 3.
Heart failure study
The third study is Pharmacological optimization in prevention in Heart Failure: A Sex-gap? and it focuses on heart failure. Heart failure means the heart does not pump as well as it should.
This Phase 3 trial has an enrollment of 368 people and includes a retrospective part and a prospective part. The prospective part asks whether women with heart failure do better at 12 months when their guideline-directed medical therapy is up-titrated, which means the doses are adjusted upward in a planned way, compared with usual care.
Losartan appears among many heart failure treatments listed in the intervention data, including several doses. The study also looks at other medicines used in heart failure care, showing that the trial is about treatment patterns and possible sex differences in care.
What the trials measure
The kidney trials measure changes in urine protein and kidney function. In FSGS, the main outcomes are percent change in urine PCR from 24-hour urine collection and the slope of eGFR, which shows how kidney function changes over time.
In IgA nephropathy, the main outcome is UPCR at set study visits, which helps show how much protein is in the urine. These outcomes matter because protein in the urine and falling kidney function can show that a kidney disease is active or getting worse.
The heart failure study measures all-cause mortality within 1 year, heart failure readmission, and worsening heart failure. It also looks at quality of life, adherence to treatment, and side effects in the prospective part of the study.
One additional safety goal appears in the FSGS study open-label extension, which checks the incidence and severity of treatment-related adverse events, including serious adverse events. An open-label extension means patients continue treatment in a study phase where everyone knows what treatment is being given.
Who the trials include
The trial data focus on adults with specific disease groups rather than on the general population. The kidney studies include adults with FSGS or IgA nephropathy, and the heart failure study focuses on people with heart failure, with a special look at women in the prospective part.
One study specifically says the FSGS patients are receiving an ARB, which shows that prior treatment is part of the study population description. Another study lists Losartan together with enalapril in the intervention data, showing that treatment comparison or background treatment is part of the research design.
Trial phases and study design
The FSGS study is in Phase 3, which is a later stage of clinical testing. The IgA nephropathy study is in Phase 4, which usually means the treatment is being studied further after earlier development stages.
The heart failure study is also in Phase 3 and has both retrospective and prospective parts. A retrospective study looks back at existing data, while a prospective study follows patients forward in time from the point they enter the study.
All three studies are interventional, meaning researchers are testing or comparing treatments rather than only observing patients. The trial data also show different comparators, including placebo and other medicines, depending on the study.
Key points from the trial data
Losartan appears in clinical trial data for both kidney disease and heart failure research. The studies are not simple drug information pages; they are research projects that test outcomes such as protein in the urine, kidney function, death, readmission, and quality of life.
The main populations are adults with FSGS, adults with IgA nephropathy, and people with heart failure, with one study paying special attention to women and possible sex gaps in treatment. Together, these trials show how Losartan is being studied in broader treatment strategies for serious long-term diseases.